DV
Dividend Vision

PRAX — Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. (PRAX)

Total return is -12.0% over the past 5.8 years, 153.8 points behind SPY at 141.8%. Its deepest 1-year drawdown was 32.6%.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, using small molecule and antisense oligonucleotide platforms with multiple candidates in NDA, Phase 3, and earlier trials. The company does not currently distribute dividends. Praxis appeals to investors with high risk tolerance seeking exposure to early-stage biotech development, particularly those interested in neurological disorder treatments.

PRAX key facts

Asset type
Stock
Asset class
Equity
Inception date
10/16/2020
Distribution frequency
None
Last close
$366.81
Market cap
$10,226,212,864
Average volume
262200.0
Beta
2.776
Payout ratio
0.0
Forward P/E
0.0
EPS
$-13.31